HeLa cell lines producing infectious replication-defective HIV virions with varyinggp160 densities indicate that increasing cellulargp160 levels cause an increase in cell-to-cell fusion, while increasing viralgp160 levels exert a biphasic effect on infectivity
AuthorBerg, Werner Mente
AdvisorLewis, George K., Ph.D.
MetadataShow full item record
Other TitlesHeLa cell lines producing infectious replication-defective HIV virions with varying gp160 densities indicate that increasing cellular gp160 levels cause an increase in cell-to-cell fusion, while increasing viral gp160 levels exert a biphasic effect on infectivity
AbstractAlthough the density of the HIV envelope protein (gp160) can vary on cells and virions, there has been little investigation into how the levels affect HIV infection and cell-to-cell fusion. To address this several cell lines stably producing infectious, replication defective virions of the T-cell line adapted HIV isolate, HXB2, were made. The cell lines varied from one another in gp160 surface expression over a five-fold range, while expressing similar levels of the Gag polyprotein. As a consequence, the cell lines collectively produced virus that varied in gp160 content over a six-fold range. With the cell lines it was observed that increasing gp160 surface expression increases cell-to-cell fusion efficiency and syncytium size. With the virus preparations it was found that gp160 levels had a biphasic affect on infection efficiency. Virus preparations with gp160 levels of 10-30 molecules per virion showed that increased gp160 content correlated with increased infection efficiency. However, at gp160 levels above 50 molecules per virion there was a decrease in infection efficiency associated with increasing gp160 per virion content. Therefore, it appears that increasing gp160 surface density exerts a qualitatively different affect on infection and cell-to-cell fusion. Based upon functional analysis, several cell lines producing the gp160 molecule from the primary isolate, JR-FL were also made. These cell lines were less characterized, and yet have the potential to be useful reagents in HIV research as well.
DescriptionUniversity of Maryland, Baltimore. Molecular and Cell Biology. Ph.D. 1999
HIV Envelope Protein gp160
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/1307
Showing items related by title, author, creator and subject.
NSAIDs and cardiovascular adverse events: Is increasing risk associated with increasing Cox-II selectivity ratios?Slagle, Ashley Fenstermacher; Simoni-Wastila, Linda (2008)Background. Recent studies have suggested there is an increased risk of cardiovascular (CV) events with some or all of the more Cox-II selective NSAIDs. One theory for this increased risk proposes that a shift in the balance between prostacyclin, an antithrombotic vasodilator that is reduced by Cox-II inhibition, and thromboxane A2, a prothrombotic vasoconstrictor that is reduced by Cox-I inhibition will theoretically increase the risk for CV and thrombotic events. This study attempts to specifically evaluate this theory by examining the association between CV events and the relative Cox-II to Cox-I selectivity of NSAIDs. Methods. Using 2000-2001 MarketScan claims data, cross-sectional and longitudinal analyses were performed. Univariate and bivariate analyses were performed to describe and compare new, adult users of NSAIDs. Propensity score matching was used to create a subset of these users, which was balanced across numerous covariates. Finally, multivariate, time to event analyses were performed using the matched sample to test the association between relative Cox-II to Cox-I selectivity ratio and possible adverse cardiovascular events. Results. Patients who were older, male, and had higher baseline cardiovascular risk were significantly more likely to receive a higher Cox-II selective drug than a lower Cox-II selective drug. In the propensity score matched sample, adjusted for confounders, the hazard of CV event was not significantly associated with increasing Cox-II selectivity ratios. Conclusion. This study shows that patients with an increased baseline risk of CV events are significantly more likely to receive a higher Cox-II selective NSAID. After controlling for these baseline differences, no significant association was found between selectivity ratios and CV events. Therefore, using Cox-II selectivity ratios to rank order NSAIDs in terms of risk of CV events is not appropriate and practitioners should not rely on selectivity ratios in making prescribing decisions. Additional studies should evaluate other potential mechanisms contributing to the CV risk of NSAIDs, while further study, in a larger sample and for a longer duration, should be performed to confirm the absence of an association between CV adverse events and Cox-II selectivity ratios.
Heterogenous Ribonucleoprotein A18 (hnRNP A18) Promotes Tumor Growth by Increasing Protein Translation of Selected Transcripts in Cancer CellsChang, Elizabeth Tsuying; Carrier, France; 0000-0002-2044-8393 (2016)The heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by coordinating the translation of selected transcripts associated with proliferation and survival. hnRNP A18 binds to and stabilizes the transcripts of pro-survival genes harboring its RNA signature motif in their 3'UTRs. Under cellular stress, hnRNP A18 binds to ATR, RPA, TRX, HIF-1? and several protein translation factor mRNAs on polysomes and increases de novo protein translation. Most importantly, down-regulation of hnRNP A18 decreases proliferation, invasion, and migration, in addition to significantly reducing tumor growth in two mouse xenograft models, melanoma and breast cancer. Moreover, tissue microarrays performed on human melanoma, prostate, breast, and colon cancer show that hnRNP A18 is over-expressed in 40 to 60% of these malignant tissue as compared to normal adjacent tissues. Immunohistochemistry data reveal that hnRNP A18 is over-expressed in the stroma and hypoxic areas of human tumors. These data thus indicate that hnRNP A18 can promote tumor growth in in vivo models by coordinating the translation of pro-survival transcripts which support the demands of proliferating cells and ultimately increase survival under cellular stress. hnRNP A18 therefore represents a new target to selectively inhibit protein translation in tumor cells.
Increasing uptake of comparative effectiveness and patient-centered outcomes research among stakeholders: Insights from conference discussionLaw, E.; Harrington, R.; Alexander, G.C. (Future Medicine Ltd., 2018)The goal of comparative effectiveness research (CER) and patient-centered outcomes research (PCOR) is to improve health outcomes by providing stakeholders with evidence directly relevant to decision making. In January 2017, the Pharmaceutical Research and Manufacturers Association Foundation, alongside the Academy for Managed Care Pharmacy, organized a conference aimed at engaging experts and opinion leaders representing clinicians, patients and payers to identify and discuss barriers and strategies to enhancing uptake and use of CER/PCOR. This report summarizes the conference discussion in the following sections: preconference survey; summary of barriers and strategies to the uptake of CER/PCOR identified by conference attendees; and future perspectives on the field. Copyright 2018 2018 Ernest Law.